Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MyNano

Financiado

Cerrado

Towards the design of Personalised Polymer based Combination Nanomedicines for A...

Towards the design of Personalised Polymer based Combination Nanomedicines for Advanced Stage Breast Cancer Patients Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted comb... ver más

31/12/2020

Fundación de la Co...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

Fundación de la Comunidad Valenciana Centro d... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Fundación de la Comunidad Va...

1.72M€ | Lider

EQUIPOS NUCLEARES SA SME

547.74K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NANOTHER Integration of Novel Nanoparticle based Technology for Thera... 12M€ Cerrado

NANOTRAC Tracing the Intracellular Fate of Anticancer Nanomedicines 100K€ Cerrado

SAF2013-44848-R POLIMEROS TERAPEUTICOS COMO AGENTES SIMPLES Y EN COMBINACION... 218K€ Cerrado

NANOTHERAPY A Novel Nanocontainer drug carrier for targeted treatment of... 150K€ Cerrado

HybridNP Remotely actuated re-shaped nanocarriers for tumour targetin... 150K€ Cerrado

CTQ2010-18195 NANOFARMACOS POLIMERICOS UTILIZADOS COMO AGENTES SIMPLES Y E... 120K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2015-05-05
Fecha Fin: 2020-12-31

Líder del proyecto

Fundación de la Comunidad Valenciana Centro d... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted combination therapies, concept I pioneered that allows enhanced therapeutic efficiency. Early clinical trials involving conjugates showed activity in chemotherapy refractory patients and reduced drug-related toxicity. However, there is a growing concern on patient variability regarding tumor patho-physiology that underlie successful therapeutic outcome. Specific biomarkers are required to select those patients most likely to show good clinical response to these therapies. The objective of MyNano is to engineer polymer-based combination therapies designed to treat metastatic breast cancer in a patient personalised manner. Therefore, novel multicomponent polymer conjugates with precise control over size, shape, solution conformation, multifunctionality and bioresponsiveness will be obtained while in parallel their structure activity relationships to underlying proposed mechanisms of action in clinically relevant models will be studied. Polyglutamates obtained by controlled polymerisation and self-assembly strategies will be the carriers. Primary breast cancer patient tissue will be used to generate cell and in vivo models representing different clinical molecular subtypes. MyNano will also investigate new combination strategies using current treatments together with inhibitors of tumor-derived exosome release pathways, phenomenon related to metastasis and resistance mechanisms. The aim is to provide a novel methodological approach that would allow by reiterative design to optimise the design of the next generation nanoconjugates for the treatment of specific metastatic cancer clinical subtypes. MyNano will be a breakthrough as it introduces a paradigm shift in the strategy to design nanomedicines in areas of unmet clinical need.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores